On June 1, 2018 CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported that it will host a conference call and live webcast on Monday, June 4th at 5:00 p.m. CT/ 6:00 p.m. ET to discuss presentations of preliminary clinical results from PROCLAIM-072, an ongoing Phase 1/2 trial evaluating CX-072, a Probody therapeutic targeting PD-L1, at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper). Conference call and webcast details are as follows (Press release, CytomX Therapeutics, JUN 1, 2018, View Source [SID1234527038]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date and Time:
Monday, June 4, 2018
5:00 p.m. Central Time/ 6:00 p.m. Eastern Time
Audio Conference Call:
U.S. Toll Free Dial-in Number: (877) 809-6037
International Dial-in Number: (615) 247-0221
Conference ID: 4294667
Live Webcast:
Access the Events and Presentations Section of CytomX’s Investor Relations section at View Source
Access the website 15 minutes prior to the start of the call to download and install any necessary audio software with slides
Replay:
A replay of the webcast will be archived and available on CytomX’s website for three months following the event.